Evommune, an inflammation‑focused biotech, filed to go public targeting roughly $150 million to advance two Phase 2 programs: EVO756, an oral MRGPRX2 antagonist, and EVO301, an IL‑18 neutralizing fusion protein. The company intends to list on the NYSE under ticker EVMN and said proceeds will support ongoing trials and topline readouts expected in 2026. Evommune’s IPO plan follows a recovering capital market for specialty biotech and comes on the heels of a large IPO by MapLight, which refreshed market appetite for immunology and neuroscience plays. Evommune highlighted promising early data in chronic spontaneous urticaria and atopic dermatitis and will use the IPO proceeds to fund pivotal‑enabling activities.